To develop an AIDS vaccine for human use as well as a suitable animal model for AIDS research, we constructed a series of HIV-1/SIVmac chimeric viruses (SHIVs). We successfully generated a SHIV (designated as NM-3rN) having the HIV-1 env gene, which enabled the evaluation of the efficacy of HIV-1 Env-targeted vaccines in macaque monkeys instead of chimpanzees. Two NM-3rN derivatives (NM-3 and NM-3n) induced long-term anti-virus immunities without manifesting the disease. The monkeys vaccinated with NM-3 or NM-3n became resistant to a challenge inoculation with NM-3rN. Serum from a monkey vaccinated with NM-3 neutralized not only the parental HIV-1 (NL432), but also an antigenically different HIV-1 (MN). In vivo experiments confirmed the heterologous protection against an SHIV having the HIV-1 (MN) env. In addition to specific immunity including neutralizing antibodies and cytotoxic T lymphocyte activity, nonspecific immunity such as natural killer activity is associated with this protection. These data suggest that the live vaccine has the ability to protect individuals against various types of HIVs. These SHIVs should contribute to the development of future anti-HIV-1 live vaccines in humans.
Introduction
The lack of a suitable animal model for evaluating vaccine candidates of human immunodeficiency virus type 1 (HIV-1) is a difficult problem in developing the vaccine, because few animal species are susceptible to HIV-1 infection. Pig-tailed macaques 1 and rabbits 2 were reported to be infected with HIV-1, but they could not be used practically. At present, chimpanzees are the only animals used for evaluation of HIV-1 vaccines, although some human trials have been conducted. 3 Chimpanzees, however, rarely show any AIDS-like disease, and their use is extremely limited for experiments because they are an endangered species. We therefore tried to generate an HIV-1 that is infectious to, and able to induce, an AIDS-like disease in macaque monkeys, by constructing HIV-1 chimeric viruses based on SIVmac (SHIVs). As a result, we succeeded in constructing chimeric viruses, which include the env gene of HIV-1 and which could infect macaque monkeys, a species that is available for experimental use. 4, 5 These chimeric viruses express the HIV-1 Env protein, and enable us to use macaque monkeys instead of chimpanzees for evaluation of vaccine candidates. This is done by vaccinating the monkeys with a vaccine candidate and then challenging them with the chimeric viruses.
In addition, SHIVs may be used as anti-HIV-1 live attenuated vaccines for humans for the following reasons: (1) SHIVinfected monkeys produced neutralizing antibodies and killer Correspondence: M Hayami, Institute for Virus Research, Kyoto University, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606, Japan T cells against HIV-1 Env without any clinical symptoms; (2) SIV Gag crossreacts with HIV-1 Gag, which can be another neutralizing epitope besides Env; (3) SIV is genetically close to HIV-2 which is less pathogenic than HIV-1, and accidental SIV infection in humans resulted in silent infection, suggesting that SIV is not pathogenic in humans; (4) these SHIVs can infect human lymphocytes, suggesting that the infection immunity by SHIVs may be induced in humans and protect humans from the HIV-1 infection. For the purpose of making a vaccine, therefore, some genes essential for pathogenicity were mutated to attenuate these chimeric viruses. We observed that the monkeys infected with these chimeric viruses were protected against a challenge infection. In this report, we present recent progress in our studies of SHIVs, and discuss their applications to the development of an AIDS vaccine.
Strategy for constructing chimeric viruses
First, each gene of HIV-1 and SIV was investigated by constructing various mutant viruses and determining their viral replication capacity and their exchangeability between the two viruses. 6, 7 As a result, the strategy for construction of chimeric viruses between HIV-1 and SIV was determined as follows: (1) vpr and nef can be sacrificed; (2) tat and TAR (in LTR) can be from different parental viruses, but rev and RRE (in env), which interact, should have the same origin; (3) gag and env can be from different origins, but gag and pol should be from the same origin.
Based on this strategy, we constructed chimeric viruses between HIV-1 and SIVmac. SIVmac is known to induce an AIDS-like disease in macaque monkeys. At first, chimeric viruses were constructed by replacing the 5′-half containing gag and pol, and the 3′-half containing env, tat and rev between HIV-1 and SIVmac, and their replicative abilities were investigated in human or monkey peripheral blood mononuclear cells (PBMC). As a result, the chimeric viruses that had the env of HIV-1 and the gag and pol of SIVmac could replicate in monkey PBMC, but the other viruses, which had the env of SIVmac and the gag and pol of HIV-1, could not 4 ( Figure 1 ). This result shows that the gag and pol genes of SIVmac determine the tropism to monkey PBMC and that the env gene has no relation to this cell tropism. This fact was unexpected because Env, whose function is to bind to cells, was generally supposed to determine the cell tropism.
Experimental infection of monkeys with HIV-1/SIVmac chimeric viruses
In the series of chimeric viruses constructed, NM-3 5, 8 and NM-3n, 9 which could replicate in monkey PBMC, were inoculated to cynomolgus monkeys intravenously (i.v.). Their abilities to infect monkeys were examined by virus recovery, the polymerase chain reaction (PCR) and antibody response ( Of two monkeys (8-and 11-year-old males) inoculated with 10 4 TCID 50 of NM-3, one developed a persistent viremic state, and anti-Env and anti-Gag antibodies were raised as expected from the structure of this chimeric virus. These antibodies had virus neutralizing activity, which neutralized NM-3 and the parental HIV-1. HIV-1 Env-specific cytotoxic T lymphocytes Table 1 Summary of experimental infection of NM-3 and NM-3n 
Experimental infection with NM-3n (weeks) 0 2  6  10  12  14  20  30  37  42  52  63  73  88 virus recovery
(CTL) were detected at 3 years post-inoculation. In the other monkey, proviral DNA was detected in PBMC only in the early period after inoculation, and anti-Env antibodies were detected for a while. Thus, this monkey was considered to be infected transiently. 5 These results showed that NM-3 infection induced both humoral and cellular anti-virus immunities in monkeys, although its infectivity was not so efficient.
Two monkeys (a 3-year-old male and a 3-year-old female) were inoculated with 10 3.5 TCID 50 of NM-3n. Viruses were occasionally re-isolated from one of these monkeys (male), and proviruses were also detected in its PBMC by PCR in the early period after inoculation. Antibodies which neutralized NM-3n and the parental HIV-1 were detected persistently in monkeys infected with NM-3n. HIV-1 Env-specific killer T cells were observed at 2 years post-inoculation in the monkey
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Viruses re-isolated from the monkeys infected with NM-3 or NM-3n basically maintained their chimeric structure, which had Env of HIV-1 and Gag of SIVmac.
Construction of a chimeric virus containing vpr and nef, which produces a more efficient infection
NM-3 and NM-3n, whose vpr genes were not intact (Figure 2) , were able to infect the monkeys, but did not induce an AIDSlike disease. Lang et al 11 reported that the vpr gene was associated with induction of AIDS-like disease. In an attempt to generate a pathogenic SHIV, the vpr of HIV-1 and the nef of SIVmac were introduced to the chimeric virus. 12 Accordingly, this chimeric virus has LTR, gag, pol, vif, vpx and nef of SIVmac and env, tat, rev, vpu and vpr of HIV-1. As this virus, termed NM-3rN, could replicate in monkey PBMC more efficiently than NM-3 and NM-3n, 10 5 TCID 50 of NM-3rN was inoculated intravenously into a total of six monkeys including cynomolgus, rhesus and pig-tailed monkeys. Viruses were continuously re-isolated from 2 w.p.i. in all the monkeys infected with NM-3rN. It was shown that this virus could infect monkeys much more efficiently than NM-3 and NM3n. 12 These results indicate that NM-3rN is useful as a challenging virus for the evaluation of vaccine candidates, because NM-3rN has HIV-1 Env, and candidates of AIDS vaccines under development are directed to an induction of an antiEnv immunity. Thus, the evaluation of vaccines has become possible in macaque monkeys instead of chimpanzees by using NM-3rN as a challenging virus. HIV-1NL432 was used to construct NM-3rN, and its V3 of Env, a primary neutralizing epitope, is of the prototypic IIIb type. We also constructed chimeric viruses from HIV-1SF13 and HIV-1HAN2, replication-competent in macaque monkeys. 13 The V3 of these chimeric viruses is an MN type which is endemic in America and Europe. The evaluation of vaccines against an MN-type virus has become possible by these chimeric viruses.
Onset of AIDS-like disease by an in vivo passaged chimeric virus
Although monkeys infected with NM-3rN have shown no clinical signs associated with AIDS up to the present (2 years post-inoculation), virus loads in some monkeys have increased. A variant of NM-3rN (R43-56) recovered at 56 w.p.i. from one monkey persistently infected with NM-3rN, improved its replication ability in monkey PBMC compared with the original NM-3rN. When R43-56 was inoculated into three monkeys, cell-associated virus loads were about 10-50 times higher than that of the original NM-3rN-inoculated monkeys. In one of the monkeys, the number of CD4
+ lymphocytes in PBMC declined to the moribund stage. The monkey lost weight ( Figure 3 ) and diarrhea was observed at the last stage. At autopsy, systemic lymphoadenopathy and follicular depletion with an expanded paracortex in the lymphnodes and spleen was observed. The monkey was also found to have acute hepatitis which was probably caused by an opportunistic viral infection. 14 The above findings suggest that the monkeys died of an AIDS-like syndrome, from which we are now trying to clone the pathogenic chimeric virus.
Development of vaccines using chimeric viruses having HIV-1 Env
Anti-HIV-1 vaccines including inactivated viral particles, recombinant viral proteins and synthetic peptides, are currently on trial in various laboratories. They are so-called 'inactivated-vaccines' which cannot replicate, and are not thought to be very efficient. In the history of vaccines against viral diseases, such as polio-myelitis and measles, live-attenuated vaccines have been proven to be the most effective by inducing long-lasting and strong humoral, cellular and other protective immunities. Therefore, attempts should be made to develop a live attenuated vaccine. For the development of a live vaccine, it is necessary to select an attenuated strain. Although high-pathogenic or low-(non-) pathogenic HIV-1 strains have been described, these reports were based only on the observations of in vitro cultures or on indirect evidence. The pathogenicities of these strains in individuals were not directly confirmed. Live attenuated vaccines so far established in other viral infections have been developed by repeated passage in cells of a different animal species. In HIV-1 vaccine development, however, this method was considered to be dangerous because a pathogenic revertant could appear due to the high mutation rate of HIV-1. In a study of SIV, it was reported that the nef gene was required to induce disease in monkeys. 10 Daniel et al 15 showed that monkeys infected with a nef-deleted non-pathogenic SIVmac were protected from a pathogenic SIVmac. They showed a new approach to attenuate viruses by deleting genes associated with the onset of disease. In our chimeric viruses, the nef and vpr of NM-3 were not intact, and the vpr of NM-3n was not intact. These viruses induced neutralizing antibodies and CTL without any clinical manifestations for 2-3 years.
We performed a protection experiment to examine the ability of immunities induced by NM-3 or NM-3n ( Table 2) . The viral and immunological status varied widely among the monkeys 'vaccinated' with NM-3 or NM-3n. Seven 'vaccinated' monkeys and four normal monkeys as a control were challenged with NM-3rN. Virus re-isolation was carried out from PBMC of these monkeys collected at 2, 6 and 10 w.p.i. Infectious viruses were recovered from all the naive monkeys at all times, but were not recovered from three of the seven vaccinated monkeys after the challenge. In the four vaccinated monkeys from which viruses were recovered, cell-associated virus loads were lower than those in the naive controls by about 10-to 100-fold. Attempts to recover virus from lymph nodes and spleen were made 10-20 weeks post-challenge and the samples were examined for virus using PCR. Viruses were not recovered from three of the seven vaccinated monkeys, but they were recovered from the other four. The differentiating PCR proved that all the viruses detected or recovered from PBMC, lymph nodes and spleens in vaccinated monkeys were NM-3 or NM-3n, not the challenging virus, NM-3rN. These results indicate that all the monkeys vaccinated with NM-3 or NM-3n were protected from challenge inoculation with NM-3rN. 16 Both cell-mediated and humoral immunities were supposed to contribute to this protection because both immunities were detected in most of the vaccinated monkeys. In two monkeys, however, no neutralizing antibodies was detected, and in one monkey, no CTL activity was found. Nevertheless, all the HIV-1/SIVmac chimeric viruses M Hayami et al
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Figure 2
Genomic structure of HIV-1, SIVmac and HIV-1/SIVmac chimeric viruses. () Sequences derived from HIV-1NL432; (ᮀ) from SIVmac239; ( ) from HIV-1MN; ( ) chimeric region of HIV-1NL432 and SIVmac239.
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Figure 3
Changes of peripheral CD4 and CD8 positive lymphocyte subsets and body weight in a monkey infected with R43-56.
monkeys were resistant to the challenge inoculation. It is noteworthy that natural killer (NK) cell activity was raised in all of these monkeys by vaccination. 16 Therefore, these vaccine viruses seem to induce an infectious immunity including not only specific neutralization and CTL activity, but also a nonspecific defense mechanism such as NK activity. This could be a big advantage of a live-attenuated vaccine, especially because of the rapid mutation and recombination of HIV-1.
There is additional evidence that the SHIV live vaccine is effective in protecting individuals from infection by various types of HIV-1. The serum of one monkey vaccinated with Table 2 Monkeys vaccinated with NM-3 or NM-3n were protected from the challenge inoculation with NM-3rN The highest serum dilution of the culture supernatants causing 50% or more reduction of RT activity of that treated with a normal monkey serum was determined. ++, Ͼ100×; +; 20-100×; −, Ͻ20×. b Target and effector cells were mixed at various ratio (100:1-12.5:1) and target cell destruction was evaluated by 51 Cr release in the supernatant. The representative value at a ratio of 100:1 was shown by ++, Ͼ25%; +, 15-25%; ±, 10-15%; −, Ͻ10%. NM-3 neutralized not only NL432, the immunizing chimeric virus and parental HIV-1, but also the antigenically different HIV-1 MN. The neutralizing titer is shown in Table 3 . It is based on the highest serum dilution of the culture supernatants that caused 50% or more reduction of RT activity compared with the RT activity of culture supernatants treated with a normal monkey serum. The main neutralizing epitope of the V3 region in NL432 is of the IIIb type, which is different from the MN type. Thus, the vaccinated monkey serum showed a broad spectrum of neutralization. An in vivo experiment also confirmed the heterologous protection by a live vaccine: two monkeys vaccinated with the chimeric virus having HIV-1 Env of the IIIb type were challenged by the chimera having an Env of MN type. No virus was recovered and no PCR product was obtained from the vaccinated monkeys (Table 4) .
To ensure the safety of a live vaccine, we also constructed a chimeric virus which was completely defective with respect to vpx, vpr and nef, and we are now examining its abilities to infect monkeys and to induce immunities. In addition, we have constructed and examined chimeric viruses using nonpathogenic SIVagm as a parental virus, which originated from an African green monkey.
17
Conclusions
To date, many attempts have been made to develop anti-HIV-1 vaccines. At present, however, there is some pessimism regarding the development of vaccines due to the failure of several vaccine trials in humans. There are difficult problems that must be overcome in order to develop anti-HIV-1 vaccines because of particular properties of HIV-1, such as a broad antigenicity. Our data suggest that a live vaccine could protect individuals from infection of various types of HIV. Another difficulty is that vaccine candidates must be evaluated directly in humans, which can take years. Chimeric viruses having HIV-1 Env have made it possible to evaluate vaccine candidates in macaque monkeys, which are available for experimental use. It is expected that vaccine development will make rapid progress once an evaluation system based on challenges with chimeric viruses has been established.
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Among the variety of candidates examined as anti-HIV-1 vaccines, a promising approach may be the use of live attenuated vaccines in view of the history of vaccines against viral diseases. However, it is difficult to use attenuated strains of HIV-1 as live vaccines. The mutation rate of HIV-1 is so high that it is hard to prevent the appearance of virulent virus. As our trial to attenuate our chimeric viruses by deleting genes is limited in the case of monkeys, these chimeric viruses may not be directly used in humans. Even in that case, this approach provides useful information on the pathogenicity of HIV infection and AIDS, and eventually will contribute to the development of future vaccines. Further efforts should be made to ensure the safety and efficacy of live-attenuated AIDS vaccine.
